Thomas Eklund has extensive experience in the pharmaceutical and medtech industry as well as the financial sector, where he has held different leading positions, including CEO and Head of Europe at Investor Growth Capital AB. Previous positions include Investment Director at Alfred Berg ABN AMRO Capital Investment AB and Vice President at Handelsbanken Markets. He is currently Chairman of the Boards of Moberg Pharma AB and Itrim AB and a board member of Boule Diagnostics AB, Biotage AB, Neoventa Medical AB, Memira AB and Rodebjer Form AB. He joined Calliditas as Chairman in August 2017.
Hilde Furberg has more than 30 years of experience in the pharmaceutical industry. She is currently Senior Vice President of Rare Disease EMEA at Sanofi Genzyme, which she joined in 2002. She opened the first operation for Genzyme in the Nordic region and has also had responsibility for Genzyme in the Benelux region. Prior to Genzyme, Hilde Furberg spent 15 years at Baxter in various business roles of increasing seniority, before which she was involved in the start-up of Calliditas. She is currently a Non-executive Director at BerGenBio and has held board memberships at Algeta ASA, Clavis Pharma ASA, Pronova Biopharma ASA, Probi AB and Copenhagen Capacity. She holds a Msc in Chemistry from the University of Oslo.
Hansson is an Investment Director at Industrifonden, an independent foundation
founded by the Swedish state in 1979 which operates on a commercial basis
without outside capital. Dr Hansson has broad experience in the life science
sector, having worked in leading and executive positions at KabiGen AB,
Symbicom AB, AstraZeneca, Arexis AB, Biovitrum AB and Karolinska Development
Olav Hellebø is CEO of UK-listed ReNeuron Group plc and Chairman and co-founder of Palma Biotech S.L. in Spain. He is an experienced pharmaceutical executive who has held senior positions in the pharmaceutical industry in both Europe and the US. Previously, Olav Hellebø was CEO of Clavis Pharma ASA and before that he was Senior Vice President of UCB Pharma and President of Immunology Operations. In this position, he built and led the global organization responsible for the successful registration and launch of Cimzia®, UCB’s antibody drug for the treatment of rheumatoid arthritis and Crohn’s disease. From 2003 to 2004, Mr Hellebø was Chief Operating Officer of Novartis UK and prior to that held a series of senior international roles at Schering-Plough, the last as Head of Schering Plough’s Oncology Biotech Division in the US. Mr Hellebø graduated summa cum laude in International Business Studies from Hofstra University, New York and received an MBA from IESE Business School, Barcelona.
Ann-Tove Kongsnes has 17 years' experience in active ownership in seed, early and expansion-stage investments, mainly working with technology companies. Ann-Tove Kongsnes is an Investment Director at Investinor, Norway’s largest investor in venture and expansion capital, and an investor in Calliditas. She holds an MSc in Economics and Business Administration from Bodø University College (HiB) and an Advanced Program in Corporate Finance from the Norwegian School of Economics (NHH). She was previously an Investment Manager at ProVenture Management AS, Business Development Manager at Leiv Eiriksson Nyskaping AS, Director of Marketing and Operations at NSEC Inc. and Marketing Manager at the Norwegian Seafood Council. In addition to Calliditas, Ms Kongsnes is a board member of Investinor’s portfolio companies Vitux AS, poLight AS, Numascale and Spinchip. She is also a deputy board member at Boost AS and Head of International Affairs at Investinor.
Bengt Julander is a pharmacist and has worked in the pharmaceutical industry since 1978. He is the CEO of Linc AB, which invests in life sciences. Since 1990, Bengt Julander has been primarily active as an investor in and a board member of pharmaceutical development companies. He has experience of developing and commercializing products. Mr Julander is currently a board member of Medivir AB, Bringwell AB, Linc AB, Livland Skog AB, Pharmalink AB, ProEquo AB, Sedana Medical AB, Stille AB, Swevet AB and a number of smaller companies.